Bulk Liquid Nitrogen (LN?) Delivery and Tank Rental Services
National Institutes of Health · NATIONAL INSTITUTES OF HEALTH OLAO
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 27-000068 in this department, oldest first.
- Oct 7, 2026 · this noticePre-solicitation
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Answer the notice: this is when the requirement can still be shaped.
- Contact the contracting officer named on the notice.
- Check who won similar work; they are the likely bidders.
What the notice says
The National Institutes of Health (NIH), Clinical Center (CC), Department of Transfusion Medicine (DTM), Center for Cellular Engineering (CCE), intends to procure continued bulk liquid nitrogen (LN?) delivery and tank rental services from Roberts Oxygen Company, Inc. The requirement supports the existing bulk LN? system serving CCE's 3T cell-manufacturing facility in Building 10 at the NIH Clinical Center. The anticipated perio of performance is from 10/16/2026 to 09/30/2027. CCE manufactures human cell- and tissue-based products used in Phase I/II clinical protocols for transplantation, adopt… (show all)
ive immunotherapy, and gene therapy and supports more than 30 patient-care clinical research protocols. The requirement includes bulk LN? deliveries to the existing tank located near the Building 10 Morgue and continued monthly rental of the installed tank. Basis for Intended Sole Source Roberts Oxygen Company, Inc. currently owns and provides the installed bulk LN? tank and supplies the liquid nitrogen used to support CCE's regulated cell-manufacturing and storage operations. The existing tank is installed on the NIH campus and connected to the CCE 3T cell-manufacturing facility. Changing suppliers would require removal of the existing tank and associated plumbing, installation of a new system, and requalification of the LN? source. Such a transition could result in additional costs and disruption to CCE's ability to manufacture and store cell therapy products. Additionally, Roberts Oxygen is currently the approved supplier for CCE manufacturing protocols. Use of an alternate supplier would require Quality Assurance review and requalification, potentially delaying patient treatment and ongoing clinical trials. Capability Statements This notice is not a request for competitive quotations or proposals. However, responsible sources that believe they can satisfy the Government's requirement may submit a capability statement demonstrating their ability to provide the required bulk LN? delivery and tank rental services. Capability statements should clearly demonstrate the vendor's ability to meet the requirement, including its ability to provide timely LN? deliveries, necessary supporting documentation for use in an FDA-regulated manufacturing environment, and any information demonstrating its ability to support the existing CCE operations. All capability statements must be received no later than October 16, 2026, at 8:00 AM Eastern Time (ET) and emailed to shasheshe.goolsby@nih.gov. The Government will consider all responses received by the stated deadline. A determination not to compete this proposed acquisition based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for determining whether to conduct a competitive procurement.
Who won similar work
258 award notices on SAM.gov in the last 24 months. Matched by: Same agency (National Institutes of Health), any industry: a loose match.
Loose match: same agency, any industry. Read the titles before treating these as competitors.
Single-winner award sizes (191): middle half $115K to $19.9M, median $1.4M; range $12K to $89.0B.
| Winner | Awards | Value | Last |
|---|---|---|---|
| BECTON, DICKINSON AND COMPANY · $BDX · $19.4B | 4 | $1.9M | Jan 26, 2026 |
| DUKE UNIVERSITY Durham NC 27705 USA | 3 | $36.3M + 1 shared | Dec 21, 2025 |
| Axle Informatics Rockville MD 20852 USA | 3 | $24.5M | May 22, 2025 |
| Axle Informatics, LLC | 3 | $15.4M | Dec 15, 2025 |
| BRUKER BIOSPIN CORP · $BRKR · $3.0B | 3 | $1.7M | Jul 30, 2026 |
| AGILENT TECHNOLOGIES INC · $A · $6.8B | 3 | $445K | Jul 24, 2025 |
| GOVERNMENT SCIENTIFIC SOURCE INC | 3 | $318K | Jan 9, 2026 |
| Multiple_Awards Bethesda MD USA | 2 | $1.1B | Dec 17, 2024 |
| FISHER BIOSERVICES INC | 2 | $148.0M | Oct 7, 2026 |
| Coriell Institute for Medical Research, Inc. | 2 | $58.8M | Aug 1, 2025 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- $BDX reported $19.4B revenue in FY2025. The median single-winner award in these 191 past awards, $1.4M, is under 0.1% of that. 10-K
- $BRKR reported $3.0B revenue in FY2025. The median single-winner award in these 191 past awards, $1.4M, is under 0.1% of that. 10-K
- $A reported $6.8B revenue in FY2025. The median single-winner award in these 191 past awards, $1.4M, is under 0.1% of that. 10-K
One award's total value against one year of revenue; many awards are paid over several years.
- Oct 9, 2026Revvity Health Sciences, Inc.$21KAutomated Cell Counter and Analyzer
- Oct 7, 2026PPD DEVELOPMENT LP$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026FISHER BIOSERVICES INC$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026BCG FEDERAL CORP.$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026ADVANCED BIOSCIENCE LABORATORIES, INC.$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026SIA PARTNERS U.S., INC.$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026AMERICAN TYPE CULTURE COLLECTION Manassas VA 20110 USA$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Sep 30, 2026Washington Metropolitan Area Transit Authority Washington DC 20024 USA$23.8MNIH TRANShare Program -WMATA SmartBenefits� Program Transit Benefit Services
- Sep 29, 2026THE BROAD INSTITUTE, INC$215KWhole genome sequencing for investigation of age-related chronic disease in HANDLS participants
- Sep 28, 2026EMORY UNIVERSITY 1599 CLIFTON ROAD NE 4TH FLOOR MAILSTOP 1599-001-1BA Atlanta GA 30322 USA$7.4M (shared ceiling)A--Recipient Epidemiology and Donor Evaluation Study
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 0 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (0 filings)
- 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
- $45K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Energy and Commerce, Senate Committee on Appropriations, Senate Committee on Health, Education, Labor, and Pensions
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 0 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 3 of the past winners are listed companies
- 0 insider buys and 5 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.